The Food and Drug Administration has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in “inordinate amounts.” The letter to Empower Pharmacy marks the first time the FDA has waded into a fierce debate about when a pharmacy’s legitimate work of customizing a medication crosses the…
GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a new economic study finds. Researchers found that patients who used the drugs, sold under brand names including Ozempic and Wegovy, took 17% less long-term sick leave than people who didn’t use the medications. The study defines long-term…
Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo’s. The lawsuit accuses Eli Lilly of misleading consumers by using outdated clinical trial data to make Zepbound and Mounjaro appear more effective than Novo’s drugs, Wegovy and Ozempic, for weight loss…
